Vor Bio jumps after late-stage data for immune disorder drug

** Shares of drug developer Vor Bio VOR.O rise ~37% to $2.26 premarket

** Co and Chinese partner RemeGen's 688331.SS experimental drug met the main goal of a late-stage study in China for the treatment of Sjögren's disease

** VOR says the drug, telitacicept, significantly reduced disease severity in patients with the autoimmune condition that damages the glands that produce and control moisture in the body

** Telitacicept showed a favorable safety profile in the study - VOR

** VOR signed a licensing deal in June to develop and commercialize telitacicept outside China

** Telitacicept is being tested to treat another immune disorder, generalized myasthenia gravis, in a global late-stage study

** Up to last close, stock was up 49.5% YTD